The prevalence of type 2 diabetes has increased as a result of rising obesity rates and the aging population. Antidiabetic drug Pioglitazone alone or in combination with metformin, repaglinide, insulin, or sulphonylurea led to both long-term and short-term improvements in glycaemic control and serum lipid profiles. Additionally, several studies have shown that Pioglitazone does not raise cardiovascular risk and might exhibit some cardiovascular protective effects.
Dr. Priyanka Joshi
Priyanka Joshi is a Doctor of Medicine and medical Advisor of USV
Dr. Rakesh Kumar Sahay
Diabetes & Endocrinology
Professor of Endocrinology in the Department of Endocrinology at Osmania Medical College
Already registered? Login